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Regional, CRC-Distant, and Dead. Quality adjusted life years
were used as the primary outcome measure. The base case analy-
sis represents the overall cost and effectiveness associated with
each screening strategy. Incremental cost-effectiveness ratios
(ICERs) were calculated for each screening strategy. One-way
sensitivity analyses were performed to assess the factors that
have the greatest effect on the cost-effectiveness of screening.
RESULTS: The most cost-effective screening strategy was Fecal
Occult Blood Test (FOBT); followed by FOBT plus aspirin,
colonoscopy, and colonoscopy plus aspirin. The ICER of FOBT
was $13,014.85 compared to natural history or no intervention.
The model was sensitive to the costs of FOBT, colonoscopy, and
aspirin. The screening strategies were sensitive to the cost of
aspirin, FOBT, and colonoscopy. CONCLUSION: Results from
the analysis showed that the most cost-effective screening strat-
egy was the use of FOBT yearly. In terms of only cost, FOBT
was the least expensive screening strategy whereas the most
expensive was colonoscopy plus COX-2 inhibitor. The results
from the study suggest that FOBT and colonoscopy, as well as
these strategies plus aspirin, are the more cost-effective of all the
screening strategies employed. FOBT plus aspirin and col-
onoscopy have similar cost-effectiveness with colonoscopy
having an ICER of only $35.43.
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COST-EFFECTIVENESS ANALYSIS OF DOCETAXEL VERSUS
OTHER REGIMENS IN THE ADJUVANT THERAPY OF EARLY
AND LOCALLY ADVANCED BREAST CANCER IN POLAND
Walczak J1, Pawlik D1,Wojcik R1, Kaczor M1, Lis J2, Nogas G1
1Arcana Institute, Cracow, Poland, 2Sanoﬁ-Aventis, Warsaw, Poland
OBJECTIVES: To compare cost effectiveness of docetaxel
chemotherapy with other adjuvant treatment regimens in early
and locally advanced breast cancer. METHODS: Cost-effective-
ness Markov model from payer perspective (health insurance and
patient), using costs information from published sources and the
patient lifetime horizon. RESULTS: Two comparisons, TAC
(docetaxel/doxorubicin/cyclophosphamide—75/50/500 mg/m2,
6 cycles) vs FAC (ﬂuorouracil/doxorubicin/cyclophophamide—
500/50/500 mg/m2, 6 cycles) and FEC + T (ﬂuorouracil/
epirubicin/cyclophosphamide—500/100/500 mg/m2, 3 cycles +
docetaxel 100 mg/m2, 3 cycles) vs FEC (ﬂuorouracil/epiru-
bicin/cyclophosphamide—500/100/500 mg/m2, 6 cycles), were
performed. One randomized clinical trial was included for each
comparison. Average costs of the treatment of early or locally
advanced breast cancer (including adjuvant chemotherapy, addi-
tional treatment—tamoxifen/radiotherapy, treatment of adverse
events and disease recurrence) and treatment effects were per
patient: TAC 42883 PLN/25,7 LYG vs FAC 8799 PLN/23,6
LYG; FEC + T 32828 PLN/26,1 LYG vs FEC 13505 PLN/24,7
LYG. ICER for TAC vs FAC comparison was 16558 PLN/LYG.
ICER for FEC + T vs FEC was 13 904 PLN/LYG. CONCLU-
SION: Docetaxel regimens are more effective and more expen-
sive in the treatment of patients with early and locally advanced
breast cancer compared with FAC and FEC chemotherapies,
ICER range 13904-16558 PLN/LYG.
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OBJECTIVES: A recent randomized phase III trial of XP vs. con-
tinuous infusional FP as ﬁrst-line therapy in patients with AGC
met its primary endpoint of non-inferior progression-free sur-
vival (PFS). There was a trend toward superior efﬁcacy seen with
the superiority test for PFS (median 5.6 months for XP vs. 5.0
for FP) and the superior response rates of XP. A pharmacoeco-
nomic model was built to compare costs of the two therapies in
an Italian setting. METHODS: Direct medical costs during the
study were estimated from the Italian hospital perspective. Costs
of the two alternative therapies were estimated based on the trial
results on actual dose and the number of administrations, and
Italian unit costs. Adverse event (AE) proﬁles were used to esti-
mate the cost of treating AEs. An expert panel estimated typical
treatment patterns and costs of treating major AEs like anemia
and febrile neutropenia. RESULTS: AE proﬁles were similar:
associated costs to treat major (grade 3/4) AEs were <€170 per
patient and were lower in the XP arm. Patients in the XP arm
received 5.2 cycles of therapy vs. 4.6 cycles of FP. The substitu-
tion of oral capecitabine for infusional 5-FU reduced the number
of hospital clinic visits by 17.6 (22.8 for FP vs. 5.2 for XP).
Chemotherapy drug costs were estimated to be €1200 greater
with XP, but drug administration costs were €2900 lower, yield-
ing a net cost saving of €1700 per patient. CONCLUSION: Oral
capecitabine in combination with cisplatin would produce sig-
niﬁcant direct medical cost savings from an Italian payer per-
spective. AE costs are similar with the two regimens. Given the
trend to superior efﬁcacy, the projected direct cost savings, and
the convenience of oral treatment, XP would be considered a
dominant (less costly and more effective) regimen for AGC from
the Italian payer perspective.
PCN15
COST-EFFECTIVENESS OF NEW TARGETED THERAPY
SUNITINIB MALATE AS SECOND LINE TREATMENT IN
METASTATIC RENAL CELL CARCINOMA IN ARGENTINA
Aiello EC1, Muszbek N2, Richardet E3, Lingua A3, Charbonneau C4,
Remák E5
1Pﬁzer Argentina, Buenos Aires, Argentina, 2UnitedBiosource
Corporation, London, UK, 3Instituto Oncológico de Córdoba,
Córdoba, Argentina, 4Pﬁzer, New York, NY, USA, 5United BioSource
Corporation, Budapest, Hungary
OBJECTIVES: To estimate the cost-effectiveness of sunitinib
malate versus palliative/best supportive care (BSC) in the treat-
ment of cytokine-refractory metastatic renal cell carcinoma
(mRCC) in patients failing on IL-2, interferon-alpha or combi-
nation of these. METHODS: A Markov model was developed
and adapted to Argentinean circumstances. Effectiveness results
were taken from a clinical trial and a US Medicare database.
Data was adjusted with general population mortality estimates
from Argentinean life tables. Utilities were collected with the
help of EQ-5D questionnaire in the clinical trial. The main
source of resource use and unit costs was an Oncology Institute
in Argentina. Costs were calculated in 2006 Argentinean pesos
(AR$). Both costs and effectiveness were discounted at a 3%
annual rate. Incremental cost-effectiveness was calculated for
progression-free month (PFM), life-year saved (LYS) and quality
adjusted life years (QALY). Both deterministic and probabilistic
sensitivity analyses were undertaken for effectiveness and cost
variables. RESULTS: Compared to BSC, sunitinib resulted in
2.61 extra PFM, 1.32 LYS and 0.98 QALY; however, at an addi-
tional cost of AR$52,243. The cost of gaining one PFM, LYS
and QALY was AR$9596, AR$39,518 and AR$53,445 respec-
tively. The result was most sensitive to effectiveness parameters.
The incremental cost/QALY was always under the US threshold
of $50,000. CONCLUSION: Though treatment with sunitinib
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is more costly than BSC, it is more effective. Using the US
$50,000/QALY incremental cost-effectiveness threshold, suni-
tinib seems to be cost-effective in the second-line treatment of
mRCC in Argentina.
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OBJECTIVES: Chronic myelogenous leukaemia (CML) is a pro-
gressive disease that is associated with signiﬁcant health and 
economic burden. Although durable response from current 
treatments such as imatinib is achievable for many patients, a
subset of patients develop resistant disease. This study aims to
predict the impact of short-term response upon the cost-
effectiveness of new interventions to treat CML. METHODS: A
Markov model was developed to estimate the non-drug costs and
health outcomes associated with treatments for chronic phase
CML. Two hypothetical treatment options were modelled, each
with a different short-term best response proﬁle. Short-term
response was deﬁned as “no response” (NR), “complete haema-
tological response” (CHR), partial cytogenetic response (PCR)
and complete cytogenetic response (CCR). Patients progressed
through the stages of the disease at different rates, based on their
short-term best response to treatment. Unit costs were drawn
from national databases, and were factored according to
resource use to estimate total costs. Because the purpose of this
study is to inform the cost-effectiveness of novel treatments, drug
costs are not included in the model. Resource use and quality-
adjusted life year (QALY) scores were stratiﬁed according to the
patient’s current health status and response level. RESULTS:
Patients who achieve no response are estimated to experience a
total of 1.48 QALYs and incur costs of £39,724 over their life-
time. Those who achieve CHR, PCR and CCR experience 5.11,
9.73 and 10.00 QALYs, and costs of £55,816, £65,610 and
£66,562 respectively. CONCLUSION: Short-term response is
related both to long-term survival and increased costs. The
increased costs associated with improved response are a result of
the patient’s improved survival and consequent increased
resource use. However, these costs may be offset by reductions
in major cost drivers such as hospitalisation and/or other
resource use as a result of the improved response.
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OBJECTIVES: Anemia is commonly experienced by cancer
patients receiving chemotherapy. Two erythropoietic agents have
been FDA-approved for ﬁxed dosing in patients with chemother-
apy-induced anemia (CIA) [epoetin alfa (EPO) 40,000 Units QW,
darbepoetin alfa (DARB) 500 mcg Q3W]. The current analysis
was conducted to compare medical costs between approved EPO
and DARB dosages based on clinical data from two 16-week,
randomized, controlled trials (Canon JNCI 2006, Waltzman
Oncologist 2005). METHODS: A cost-minimization analysis
was utilized to compare direct medical costs (drug acquisition
and visit costs) of treating patients with EPO QW versus DARB
Q3W. Drug cost was based on December 2006 U.S. wholesale
acquisition cost (EPO $12.52/1000 Units; DARB $4.446/mcg).
Visit cost was calculated based on physician ofﬁce visit and injec-
tion cost ($53.27). Sensitivity analyses were conducted on drug
cost, physician visit cost, hemoglobin monitoring, and transfu-
sion requirements. RESULTS: Results from the base case sce-
nario showed that direct medical costs of treating patients with
DARB Q3W was $1595 more expensive (28% cost premium)
than treating patients with EPO QW ($5795 for EPO QW vs.
$7390 for DARB Q3W). Drug cost represented °Y´90% of total
direct medical costs in both groups (EPO : drug cost $5239, visit
cost $555; DARB : drug cost $7149, visit cost $240). Sensitivity
analyses revealed the cost premium associated with DARB Q3W
therapy to be between 13% and 42%, indicating that direct
medical cost of EPO QW therapy was consistently lower than
that of DARB Q3W. CONCLUSION: This economic analysis
demonstrated that direct medical costs for DARB Q3W therapy
was consistently higher than EPO QW, with cost premiums asso-
ciated with DARB Q3W ranging from 13%–42%. Drug cost was
the major driver of total direct medical cost in both groups.
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OBJECTIVES: Malignant metastatic melanoma (MMM), the
most serious form of skin cancer, currently accounts for 79% of
all skin cancer deaths, and is becoming increasingly common.
MMM patients have limited treatment options and low survival
rates. The ﬁve-year survival rate for patients with regional
melanoma is 63.8%, compared to 16.0% for patients with
metastatic melanoma. Despite the importance of this cancer, data
on its economic burden are limited. METHODS: A prevalence-
based model was developed to estimate the aggregate annual cost
burden attributable to MMM from a societal perspective, includ-
ing costs of medical treatment and lost productivity in the US.
Key relationships represented in the model include the annual
numbers of patients treated for MMM by age group; utilization
of cancer-speciﬁc treatments; unit costs of these treatments; work
days missed by these patients; and wage rates. Data sources
included the linked Surveillance, Epidemiology and End Results
(SEER)–Medicare database, the Bureau of Labor Statistics, and
published literature. RESULTS: The annual prevalence of MMM
in the US was estimated to be 5778 cases. The associated annual
cost burden was estimated at approximately $202 million
($34,991 per patient) in 2005. Health care costs and lost pro-
ductivity accounted for 87.1% ($176 million) and 12.9% ($26
million) of the total burden, respectively. The principal cost
driver was cancer-related hospitalization (accounting for 31.4%
of total health care costs) for procedures including lym-
phadenectomy, radiofrequency ablation, chemotherapy, and
arterial embolization. SNF services, hospice care, physician ser-
vices and outpatient hospital services accounted for 5.8%, 5.9%,
11.6% and 8.0% of health care costs, respectively. Sensitivity
analyses varying assumptions regarding health care utilization
and wage rates resulted in a range in the estimated annual burden
from $207 to $216 million. CONCLUSION: The economic
burden of MMM in the US is substantial. New therapies for
MMM have the potential to yield considerable economic bene-
ﬁts to society.
